ReviewJournal of lipid research2012
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.
Review in Journal of lipid research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 284 citations in OpenAlex.
- Changes in bile acid subtypes and improvements in lipid metabolism and atherosclerotic cardiovascular disease risk: the Preventing Overweight Using Novel Dietary Strategies (POUNDS Lost) trial.The American journal of clinical nutrition · 2024Trial
- A lipidomic and metabolomic signature of a very low-carbohydrate high-fat diet and high-intensity interval training: an additional analysis of a randomized controlled clinical trial.Metabolomics : Official journal of the Metabolomic Society · 2023Trial
- Trial
- Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β3-Adrenergic Receptor Agonist.Diabetes · 2018Trial
- Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.Alimentary pharmacology & therapeutics · 2018Trial
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.Lancet (London, England) · 2015Trial
- Limonin attenuates hyperlipidemia by regulating the gut microbiota-bile acid-farnesoid X receptor axis.Journal of translational medicine · 2026Article
- The Collaborative Collapse: Bile Acid Dysmetabolism as a Central Pathogenic Driver in Canine and Feline Multi-Systemic Disorders-From Mechanisms to Precision Therapeutics.Veterinary sciences · 2026Review
- Genetic and dietary determinants of gut microbiome-bile acid interactions in the BXD genetic reference population.Nature communications · 2025Article
- Role of gut microbiota in the pathogenesis of metabolic syndrome: an updated comprehensive review from mechanisms to clinical implications.Annals of medicine and surgery (2012) · 2025Review
- Effects of Obeticholic Acid Treatment on Primary Human Hepatocytes in a Novel Tri-Culture Model System.Cells · 2025Article
- Gut Microbiota Dysbiosis and Its Impact on Type 2 Diabetes: From Pathogenesis to Therapeutic Strategies.Metabolites · 2025Review
- Unresolved alterations in bile acid composition and dyslipidemia in maternal and cord blood after UDCA treatment for intrahepatic cholestasis of pregnancy.American journal of physiology. Gastrointestinal and liver physiology · 2025Article
- Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD.Antioxidants (Basel, Switzerland) · 2025Review
- Targeted metabolomic profiling reveals inflammation-associated longitudinal changes in plasma metabolites following on-pump coronary bypass surgery.Frontiers in medicine · 2025Article
- Differential effects of electroacupuncture and manual acupuncture on spontaneously hypertensive rats: insights from intestinal microbiota and metabolomics.Frontiers in molecular biosciences · 2025Article
- A small molecule esculetin accelerates postprandial lipid clearance involving activation of C/EBPβ and CD36-mediated phagocytosis by adipose tissue macrophages.Theranostics · 2025Article
- The changing metabolic landscape of bile acids - keys to metabolism and immune regulation.Nature reviews. Gastroenterology & hepatology · 2024Review
- Hepatic-Accumulated Obeticholic Acid and Atorvastatin Self-Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic-Associated Fatty Liver Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Bile acids and incretins as modulators of obesity-associated atherosclerosis.Frontiers in cardiovascular medicine · 2024Review
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyslipidemia is an important risk factor for cardiovascular disease (CVD) and atherosclerosis. When dyslipidemia coincides with other metabolic disorders such as obesity, hypertension, and glucose intolerance, defined as the metabolic syndrome (MS), individuals present an elevated risk to develop type 2 diabetes (T2D) as well as CVD. Because the MS epidemic represents a growing public health problem worldwide, the development of therapies remains a major challenge. Alterations of bile acid pool regulation in T2D have revealed a link between bile acid and metabolic homeostasis. The bile acid receptors farnesoid X receptor (FXR) and TGR5 both regulate lipid, glucose, and energy metabolism, rendering them potential pharmacological targets for MS therapy. This review discusses the mechanisms of metabolic regulation by FXR and TGR5 and the utility relevance of natural and synthetic modulators of FXR and TGR5 activity, including bile acid sequestrants, in the treatment of the MS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.